Accelerate Diagnostics (STU:1A80) Total Stockholders Equity : €-53.52 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Total Stockholders Equity?

Accelerate Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €-53.52 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Accelerate Diagnostics's Book Value per Share for the quarter that ended in Dec. 2024 was €-2.12. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Accelerate Diagnostics's Debt-to-Equity for the quarter that ended in Dec. 2024 was -1.19.

Accelerate Diagnostics Total Stockholders Equity Historical Data

The historical data trend for Accelerate Diagnostics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Total Stockholders Equity Chart

Accelerate Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

-51.63

-31.04

-21.02

-18.24

-53.52

Accelerate Diagnostics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															-18.24	-23.72	-32.41	-43.68	-53.52

Accelerate Diagnostics (STU:1A80) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Accelerate Diagnostics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-53.518	-	0)	/	25.187
	=	-2.12

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Accelerate Diagnostics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.368	+	47.212)	/	-53.518
	=	-1.19

Accelerate Diagnostics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

AXDX:USA AXDX:Mexico 0H8E:UK 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Accelerate Diagnostics Headlines

No Headlines